Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470951 | 0.83 | BACE1 (0.51) | BACE1MEN1KMT2AKDM4ECSNK1D | |
| SCHEMBL14570537 | 0.80 | KDM4E (0.47) | BACE1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL5466370 | 0.78 | BACE1 (0.47) | BACE1KDM4ECSNK1DMCHR1SCN9A | |
| SCHEMBL11466806 | 0.77 | LMNA (0.51) | MEN1KMT2AKDM4ECSNK1DLMNA | |
| SCHEMBL5466721 | 0.76 | BACE1 (0.57) | BACE1KDM4EMCHR1SCN9A | |
| SCHEMBL14018671 | 0.76 | BACE1 (0.57) | BACE1KDM4EMCHR1DYRK1A | |
| SCHEMBL3533290 | 0.75 | CYP1A2 (0.62) | MEN1KMT2AKDM4E | |
| SCHEMBL27459309 | 0.75 | ALDH1A1 (0.44) | MEN1KMT2ADYRK1ALMNA | |
| SCHEMBL15505079 | 0.74 | ALDH1A1 (0.48) | MEN1KMT2AKDM4ELMNACFTR | |
| SCHEMBL5473781 | 0.74 | BACE1 (0.54) | BACE1KDM4EMCHR1SCN9ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | PFIZER INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | PFIZER INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | CETP, LCAT, MTTP | BACE1 1346/4885MEN1 4063/4885KMT2A 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.